Anti-obesity effect of the above-ground part of Valeriana dageletiana nakai ex F. Maek extract in high-fat diet-induced obese C57BL/6N mice

Nutrients

Volumn 9, Issue 7, 2017, Pages

  Wang, Zhiqiang ^a,b   Hwang, Seung Hwan ^b   Kim, Ju Hee ^b   Lim, Soon Sung ^b  

^a HEBEI UNIVERSITY   (China)

^b Hallym University   (South Korea)

Author keywords

3T3 L1; Adipogenesis; Epididymal adipose tissue; Fatty liver; Herbal medicine; Lipid profile; Lipogenesis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIOBESITY AGENT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; GARCINIA CAMBOGIA EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VALERIANA DAGELETIANA EXTRACT; ANTILIPEMIC AGENT; VALERIAN;

ADIPOCYTE; ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOBESITY ACTIVITY; ARTICLE; BODY WEIGHT; CELL CULTURE; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG ACTIVITY; FOOD INTAKE; GARCINIA CAMBOGIA; GENE EXPRESSION; HISTOLOGY; LIPID DIET; LIPOGENESIS; MALE; MOUSE; MTS ASSAY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REAL TIME POLYMERASE CHAIN REACTION; UREA NITROGEN BLOOD LEVEL; VALERIANA; 3T3-L1 CELL LINE; AERIAL PLANT PART; ANATOMY AND HISTOLOGY; ANIMAL; C57BL MOUSE; CELL SURVIVAL; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; EATING; GARCINIA; GENE EXPRESSION REGULATION; GENETICS; LIPID METABOLISM; LIVER; METABOLISM; OBESITY;

3T3-L1 CELLS; ADIPOGENESIS; ANIMALS; ANTI-OBESITY AGENTS; CELL SURVIVAL; DIET, HIGH-FAT; EATING; GARCINIA; GENE EXPRESSION REGULATION; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIVER; MICE; MICE, INBRED C57BL; OBESITY; PLANT COMPONENTS, AERIAL; PLANT EXTRACTS; VALERIAN;

EID: 85022021295     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9070689     Document Type: Article

References (48)

1. Stevens, G.A.; Singh, G.M.; Lu, Y.; Danaei, G.; Lin, J.K.; Finucane, M.M.; Bahalim, A.N.; McIntire, R.K.; Gutierrez, H.R.; Cowan, M.; et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul. Health Metr. 2012, 10, 22. [CrossRef] [PubMed]
2. Flier, J.S. Obesity wars: Molecular progress confronts an expanding epidemic. Cell 2004, 116, 337–350. [CrossRef]
3. Christodoulides, C.; Lagathu, C.; Sethi, J.K.; Vidal-Puig, A. Adipogenesis and WNT signaling. Trends Endocrinol. Metab. 2009, 20, 16–24. [CrossRef] [PubMed]
4. World Health Organization. What Are Overweight and Obesity, Facts About Overweight and Obesity. In Report of a WHO Consultation on Overweight and Obesity; World Health Organization: Geneva, Switzerland, 2012.
5. Girard, J.; Perdereau, D.; Foufelle, F.; Prip-Buss, C.; Ferré, P. Regulation of lipogenic enzyme gene expression by nutrients and hormones. FASEB J. 1994, 8, 36–42. [PubMed]
6. Lefterova, M.I.; Lazar, M.A. New developments in adipogenesis. Trends Endocrinol. Metab. 2009, 20, 107–114. [CrossRef] [PubMed]
7. Ntambi, J.M.; Young-Cheul, K. Adipocyte differentiation and gene expression. J. Nutr. 2000, 130, 3122S–3126S. [PubMed]
8. Morrison, R.F.; Farmer, S.R. Hormonal signaling and transcriptional control of adipocyte differentiation. J. Nutr. 2000, 130, 3116S–3121S. [PubMed]
9. Abdelmalek, M.F.; Lazo, M.; Horska, A.; Bonekamp, S.; Lipkin, E.W.; Balasubramanyam, A.; Bantle, J.P.; Johnson, R.J.; Diehl, A.M.; Clark, J.M.; et al. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology 2012, 56, 952–960. [CrossRef] [PubMed]
10. Alwahsh, S.M.; Dwyer, B.J.; Forbes, S.; van Thiel, D.H.; Starkey Lewis, P.J.; Ramadori, G. Insulin production and resistance in different models of diet-induced obesity and metabolic syndrome. Int. J. Mol. Sci. 2017, 18, 285. [CrossRef] [PubMed]
11. Savard, C.; Tartaglione, E.V.; Kuver, R.; Geoffrey Haigh, W.; Farrell, G.C.; Subramanian, S.; Chait, A.; Yeh, M.M.; Quinn, L.S.; Ioannou, G.N. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2013, 57, 81–92. [CrossRef] [PubMed]
12. Alwahsh, S.M.; Xu, M.; Schultze, F.C.; Wilting, J.; Mihm, S.; Raddatz, D.; Ramadori, G. Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. PLoS ONE 2014, 9, e104220. [CrossRef] [PubMed]
13. Gwon, S.Y.; Choi, W.H.; Lee, D.H.; Ahn, J.Y.; Jung, C.H.; Moon, B.K.; Ha, T.Y. Shikonin protects against obesity through the modulation of adipogenesis, lipogenesis, and β-oxidation in vivo. J. Funct. Foods 2015, 16, 484–493. [CrossRef]
14. Baby, R.; Cabezas, M.; Castro, E.; Filip, R.; Walsöe de Reca, N.E. Quality control of medicinal plants with an electronic nose. Sens. Actuators B 2005, 106, 24–28. [CrossRef]
15. Wang, J.; Zhao, J.; Liu, H.; Zhou, L.; Liu, Z.; Wang, J.; Han, J.; Yu, Z.; Yang, F. Chemical analysis and biological activity of the essential oils of two valerianaceous species from China: Nardostachys chinensis and Valeriana officinalis. Molecules 2010, 15, 6411–6422. [CrossRef] [PubMed]
16. Blumenthal, M. The Complete German Commission E monographs. In Therapeutic Guide to Herbal Medicines; American Botanical Council: Austin, TX, USA, 1998.
17. Kim, K.Y.; Lee, H.N.; Kim, Y.J.; Park, T. Garcinia cambogia extract ameliorates visceral adiposity in C57BL/6J mice fed on a high-fat diet. Biosci. Biotechnol. Biochem. 2008, 72, 1772–1780. [CrossRef] [PubMed]
18. Lee, J.H.; Cho, H.D.; Jeong, J.H.; Lee, M.K.; Jeong, Y.K.; Shim, K.H.; Seo, K.I. New vinegar produced by tomato suppresses adipocyte differentiation and fat accumulation in 3T3-L1 cells and obese rat model. Food Chem. 2013, 141, 3241–3249. [CrossRef] [PubMed]
19. Kim, J.H.; Kim, O.K.; Yoon, H.G.; Park, J.; You, Y.; Kim, K.; Lee, Y.H.; Choi, K.C.; Lee, J.; Jun, W. Anti-obesity effect of extract from fermented Curcuma longa L. through regulation of adipogenesis and lipolysis pathway in high-fat diet-induced obese rats. Food Nutr. Res. 2016, 60, 30428. [CrossRef] [PubMed]
20. 1H NMR-based metabonomics approach in a rat model of acute liver injury and regeneration induced by CCl4 administration. Toxicology 2013, 303C, 115–124. [CrossRef] [PubMed]
21. Zhang, X.; Wu, C.; Wu, H.; Sheng, L.; Su, Y.; Zhang, X.; Luan, H.; Sun, G.; Sun, X.; Tian, Y.; et al. Anti-hyperlipidemic effects and potential mechanisms of action of the caffeoylquinic acid-rich Pandanus tectorius fruit extract in hamsters fed a high fat-diet. PLoS ONE 2013, 8, e61922. [CrossRef] [PubMed]
22. Tarantino, G. Should nonalcoholic fatty liver disease be regarded as a hepatic illness only? World J. Gastroenterol. 2007, 13, 4669–4672. [CrossRef] [PubMed]
23. Pischon, T.; Nöthlings, U.; Boeing, H. Obesity and cancer. Proc. Nutr. Soc. 2008, 67, 128–145. [CrossRef] [PubMed]
24. Ono, Y.; Hattori, E.; Fukaya, Y.; Imai, S.; Ohizumi, Y. Antiobesity effect of Nelumbo nuciferaleaves extract in mice and rats. J. Ethnopharmacol. 2006, 106, 238–244. [CrossRef] [PubMed]
25. Seo, J.B.; Choe, S.S.; Jeong, H.W.; Park, S.W.; Shin, H.J.; Choi, S.M.; Park, J.Y.; Choi, E.W.; Kim, J.B.; Seen, D.S.; et al. Anti-obesity effects of Lysimachia foenum-graecum characterized by decreased adipogenesis and regulated lipid metabolism. Exp. Mol. Med. 2011, 43, 205–215. [CrossRef] [PubMed]
26. Sclafani, A.; Ackroff, K. Role of gut nutrient sensing in stimulating appetite and conditioning food preferences. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302, 1119–1133. [CrossRef] [PubMed]
27. Woods, S.C. The control of food intake: Behavioral versus molecular perspectives. Cell Metab. 2009, 9, 489–498. [CrossRef] [PubMed]
28. Shechter, A.; Schwartz, G.J. Gut-brain nutrient sensing in food reward. Appetite 2016, S0195-6663, 30900-X. [CrossRef] [PubMed]
29. Borriello, A.; Bencivenga, D.; Caldarelli, I.; Tramontano, A.; Borgia, A.; Zappia, V.; Della, R.F. Resveratrol: From basic studies to bedside. Cancer Treat. Res. 2014, 159, 167–184. [PubMed]
30. Park, S.J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Luo, H.; Ke, H.; Rehmann, H.; Taussig, R.; Brown, A.L.; et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148, 421–433. [CrossRef] [PubMed]
31. Lai, C.S.; Wu, J.C.; Pan, M.H. Molecular mechanism on functional food bioactivities for anti-obesity. Curr. Opin. Food Sci. 2015, 2, 9–13. [CrossRef]
32. Wong, C.P.; Kaneda, T.; Morita, H. Plant natural products as an anti-lipid droplets accumulation agent. J. Nat. Med. 2014, 68, 253–266. [CrossRef] [PubMed]
33. Furuhashi, M.; Saitoh, S.; Shimamoto, K.; Miura, T. Fatty acid-binding protein 4 (FABP4): Pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin. Med. Insights Cardiol. 2014, 8, 23–33. [CrossRef] [PubMed]
34. Ahmed, M.H.; Byrne, C.D. Modulation of sterol regulatory element binding proteins (SREBPS) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov. Today 2007, 12, 740–747. [CrossRef] [PubMed]
35. Li, Z.Z.; Berk, M.; McIntyre, T.M.; Feldstein, A.E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: Role of stearoyl-COA desaturase. J. Biol. Chem. 2009, 284, 5637–5644. [CrossRef] [PubMed]
36. Amy, C.M.; Williams-Ahlf, B.; Naggert, J.; Smith, S. Molecular cloning of the mammalian fatty acid synthase gene and identification of the promoter region. Biochem. J. 1990, 271, 675–679. [CrossRef] [PubMed]
37. Sultan, S.; Pascucci, M.; Ahmad, S.; Malik, I.A.; Bianchi, A.; Ramadori, P.; Ahmad, G.; Ramadori, G. LIPOCALIN-2 is a majore acute-phase protein in a rat and mouse model of sterile abscess. Shock 2012, 37, 191–196. [PubMed]
38. Asimakopoulou, A.; Fülöp, A.; Borkham-Kamphorst, E.; van de Leur, E.; Gassler, N.; Berger, T.; Beine, B.; Meyer, H.E.; Mak, T.W.; Hopf, C.; et al. Altered mitochondrial and peroxisomal integrity in llipocalin-2-deficient mice with hepatic steatosis. Biochim. Biophys. Acta 2017. [CrossRef] [PubMed]
39. Alwahsh, S.M.; Xu, M.; Seyhan, H.A.; Ahmad, S.; Mihm, S.; Ramadori, G.; Schultze, F.C. Diet high in fructose leads to an overexpression of lipocalin-2 in rat fatty liver. World J. Gastroenterol. 2014, 20, 1807–1821. [CrossRef] [PubMed]
40. Finelli, C.; Tarantino, G. Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients? J. Gastrointestin. Liver Dis. 2012, 21, 293–302. [PubMed]
41. Godos, J.; Federico, A.; Dallio, M.; Scazzina, F. Mediterranean diet and nonalcoholic fatty liver disease: Molecular mechanisms of protection. Int. J. Food Sci. Nutr. 2017, 68, 18–27. [CrossRef] [PubMed]
42. Ouyang, X.; Cirillo, P.; Sautin, Y.; Mc Call, S.; Bruchette, J.L.; Diehl, A.M.; Johnson, R.J.; Abdelmalek, M.F. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol. 2008, 48, 993–999. [CrossRef] [PubMed]
43. Bray, G.A.; Nielsen, S.J.; Popkin, B.M. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am. J. Chin. Nutr. 2004, 79, 537–543.
44. Poutahidis, T.; Kleinewietfeld, M.; Smillie, C.; Levkovich, T.; Perrotta, A.; Bhela, S.; Varian, B.J.; Ibrahim, Y.M.; Lakritz, J.R.; Kearney, S.M.; et al. Microbial reprogramming inhibits western diet-associated obesity. PLoS ONE 2013, 8, e68596. [CrossRef] [PubMed]
45. Traversy, G.; Chaput, J.P. Alcohol consumption and obesity: An update. Curr. Obes. Rep. 2015, 4, 122–130. [CrossRef] [PubMed]
46. Alwahsh, S.M.; Ramadori, G. How does bariatric surgery improve type II diabetes? The “Neglected” importance of the liver in clearing glucose and insulin from the portal blood. J. Obes. Weight Loss Ther. 2015, 5, 1000280. [CrossRef]
47. Dib, N.; Kiciak, A.; Pietrzak, P.; Ferenc, K.; Jaworski, P.; Kapica, M.; Tarnowski, W.; Zabielski, R. Early-effect of bariatric surgery (Scopinaro method) on intestinal hormones and adipokines in insulin resistant Wistar rat. J. Physiol. Pharmacol. 2013, 64, 571–577. [PubMed]
48. Spruss, A.; Kanuri, G.; Stahl, C.; Bischoff, S.C.; Bergheirm, I. Metformin protects against the development of fructose-induced steatosis in mice: Role of the intestinal barrier function. Lab. Investig. 2012, 92, 1020–1032. [CrossRef] [PubMed]